PMC:7781431 / 1570-3027
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
73 | 48-61 | Species | denotes | coronaviruses | Tax:11118 |
74 | 63-108 | Species | denotes | severe acute respiratory syndrome coronavirus | Tax:694009 |
75 | 110-118 | Species | denotes | SARS-CoV | Tax:694009 |
76 | 124-180 | Species | denotes | middle east respiratory syndrome coronavirus (MERS- CoV) | Tax:1335626 |
77 | 204-209 | Species | denotes | human | Tax:9606 |
78 | 321-332 | Species | denotes | coronavirus | Tax:11118 |
79 | 334-381 | Species | denotes | severe acute respiratory syndrome coronavirus 2 | Tax:2697049 |
80 | 383-393 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
81 | 658-668 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
82 | 836-846 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
83 | 847-855 | Species | denotes | patients | Tax:9606 |
84 | 1047-1057 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
85 | 1308-1318 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
86 | 1137-1142 | Chemical | denotes | lipid | MESH:D008055 |
87 | 239-248 | Disease | denotes | mortality | MESH:D003643 |
88 | 729-738 | Disease | denotes | mortality | MESH:D003643 |
89 | 894-903 | Disease | denotes | infection | MESH:D007239 |
90 | 926-938 | Disease | denotes | inflammation | MESH:D007249 |
91 | 1190-1202 | Disease | denotes | inflammation | MESH:D007249 |
92 | 1280-1296 | Disease | denotes | viral infections | MESH:D001102 |
93 | 1440-1456 | Disease | denotes | viral infections | MESH:D001102 |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T5 | 670-684 | Phenotype | denotes | cytokine storm | http://purl.obolibrary.org/obo/HP_0033041 |
T6 | 887-903 | Phenotype | denotes | severe infection | http://purl.obolibrary.org/obo/HP_0032169 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T12 | 0-12 | Sentence | denotes | Introduction |
T13 | 13-269 | Sentence | denotes | The unexpected emergence of deadly coronaviruses, severe acute respiratory syndrome coronavirus (SARS-CoV) and middle east respiratory syndrome coronavirus (MERS- CoV) significantly affected human health, leading to increased mortality and life disruption. |
T14 | 270-535 | Sentence | denotes | Recently, a third highly pathogenic and infectious coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged as a deadly pandemic calling for intense research efforts on its pathogenicity mechanism and development of therapeutic strategies. |
T15 | 536-904 | Sentence | denotes | Among others, pro-resolving mediators have been investigated as a therapeutic opportunity for treatment and management of SARS-CoV-2; cytokine storm has been associated with severe illness and mortality, with many studies reporting higher concentrations of pro-inflammatory cytokines in severely ill SARS-CoV-2 patients as compared to those with less severe infection. |
T16 | 905-1058 | Sentence | denotes | Hence, resolution of inflammation through selective counter-regulation of cytokines has been identified as a potential therapeutic target for SARS-CoV-2. |
T17 | 1059-1319 | Sentence | denotes | In this review, we discussed the characteristics of specialized pro-resolving lipid mediators (SPMs) that induce the resolution of inflammation and reviewed evidence from recent studies on SPMs as therapeutic options for viral infections, including SARS-CoV-2. |
T18 | 1320-1457 | Sentence | denotes | We hope that this review will be of great help in guiding researchers who are exploring SPMs as therapeutic targets for viral infections. |